Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EQUIFAX INCEFX · Entity 3235 | President-USIS | July 27, 2018 | July 31, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EQUIFAX INC
Report date July 27, 2018 · Filed July 31, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,468 |
Reported balance
After 2018-07-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-07-27 · Grant · Acquired 4,049 · Balance 29,468 F1: Special equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 7/27/2021. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. |
Filing footnotes · ownership attribution and instrument terms
F1: Special equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 7/27/2021.
F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2018 Filed Jul 31, 2018 20:52 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 4,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-012073 · doc4.xml · nonDerivative · entry 1 Barros Paulino R · CIK 0001490964 · President-USIS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,468 F1 · security: Special equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 7/27/2021. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:19 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 5,974 | $0.00 Strike: $121.35 | $0.00 |
DisclosureSEC source: 0001225208-18-005684 · doc4.xml · derivative · entry 2 Barros Paulino R · CIK 0001490964 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,974 Underlying: Common Stock · 5,974 shares Expires 2028-03-05 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 3/5/2019. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:19 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 1,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-005684 · doc4.xml · nonDerivative · entry 1 Barros Paulino R · CIK 0001490964 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,316 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 3/5/2021. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 22:35 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 5,013 | $117.46 | $588,826.98 |
DisclosureSEC source: 0001225208-18-003598 · doc4.xml · nonDerivative · entry 2 Barros Paulino R · CIK 0001490964 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,822 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in the corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 22:35 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 8,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003598 · doc4.xml · nonDerivative · entry 1 Barros Paulino R · CIK 0001490964 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,835 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in the corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:14 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 13,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018213 · doc4.xml · nonDerivative · entry 1 Barros Paulino R · CIK 0001490964 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,020 F1 · security: Award of restricted stock units. The stock vests 100% on 12/1/2020. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 20:59 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 8,849 | $131.00 | $1,159,257.05 |
DisclosureSEC source: 0001225208-17-005275 · doc4.xml · nonDerivative · entry 1 Barros Paulino R · CIK 0001490964 · Pres-USIS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,737 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $131.00 to $131.06, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 21:11 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 7,483 | $129.36 | $968,000.88 |
DisclosureSEC source: 0001225208-17-004316 · doc4.xml · nonDerivative · entry 2 Barros Paulino R · CIK 0001490964 · Pres-USIS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,586 Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 21:11 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 10,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004316 · doc4.xml · nonDerivative · entry 1 Barros Paulino R · CIK 0001490964 · Pres-USIS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,069 Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 11:02 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 5,580 | $0.00 Strike: $129.93 | $0.00 |
DisclosureSEC source: 0001225208-17-003815 · doc4.xml · derivative · entry 2 Barros Paulino R · CIK 0001490964 · Pres-USIS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,580 Underlying: Common Stock · 5,580 shares Expires 2027-02-16 F2 · derivative.exercise_date: The option vests in three equal annual increments beginning 2/16/2018. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 11:02 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 1,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-003815 · doc4.xml · nonDerivative · entry 1 Barros Paulino R · CIK 0001490964 · Pres-USIS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,181 F1 · security: Award of restricted stock units. The stock vests 100% on 2/16/2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.